Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿° ½ÃÀå : ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø - Ä¡·á À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°, °æÀﺰ ºÎ¹®(2020-2030F)
Systemic Juvenile Idiopathic Arthritis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
»óǰÄÚµå : 1703266
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 183 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,957,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,575,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿°(sJIA) ½ÃÀåÀº 2024³â¿¡ 18¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í, ¿¹Ãø ±â°£ Áß 4.61%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇϸç, 2030³â±îÁö 24¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿°ÀÇ Èñ¼Ò ¹× ½Éµµ ¼­ºêŸÀÔÀÎ Àü½Å¼º JIAÀÇ °³¹ß, Áø´Ü, Ä¡·á, °ü¸®¸¦ Æ÷°ýÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030
½ÃÀå ±Ô¸ð : 2024³â 18¾ï 3,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 24¾ï ´Þ·¯
CAGR : 2025-2030³â 4.61%
±Þ¼ºÀå ºÎ¹® ¿Â¶óÀÎ ¾à±¹
ÃÖ´ë ½ÃÀå ºÏ¹Ì

sJIA´Â Àü½Å ¿°Áõ, °í¿­, ÇǺΠ¹ßÁø, °üÀýÅë, Àå±â ¼Õ»óÀ» Æ÷ÇÔÇÑ ÇÕº´Áõ ¹ß»ý °¡´É¼ºÀÌ ÀÖ´Â º¹ÀâÇÑ ÀÚ°¡¸é¿ªÁúȯÀ¸·Î ÁÖ·Î ¼Ò¾Æ¿¡°Ô ¹ßº´ÇÏ´Â ÁúȯÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀº ȯÀÚÀÇ ¿¹ÈÄ¿Í »îÀÇ ÁúÀ» °³¼±Çϱâ À§ÇÑ ÀǾàǰ, »ý¹°Á¦Á¦, ÀÇ·á±â±â, ÁöÁö¿ä¹ý Àü·« µî ±¤¹üÀ§ÇÑ Ä¡·á ¼Ö·ç¼Ç¿¡ °ÉÃÄ ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

»ý¹°Á¦Á¦ÀÇ Áøº¸

ÁÖ¿ä ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦

³ôÀº Ä¡·áºñ

ÁÖ¿ä ½ÃÀå µ¿Çâ

¸ÂÃãÇü ÀÇ·á

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿° ½ÃÀå Àü¸Á

Á¦6Àå ºÏ¹ÌÀÇ Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿° ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿° ½ÃÀå Àü¸Á

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿° ½ÃÀå Àü¸Á

Á¦9Àå ³²¹ÌÀÇ Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿° ½ÃÀå Àü¸Á

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿° ½ÃÀå Àü¸Á

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå PESTEL ºÐ¼®

Á¦14Àå Porter's Five Forces ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

Á¦16Àå Àü·«Àû Á¦¾È

Á¦17Àå Á¶»çȸ»ç ¼Ò°³¡¤¸éÃ¥»çÇ×

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market was valued at USD 1.83 billion in 2024 and is projected to reach USD 2.40 billion by 2030, registering a compound annual growth rate (CAGR) of 4.61% during the forecast period. This market encompasses the development, diagnosis, treatment, and management of systemic JIA-a rare and severe subtype of juvenile idiopathic arthritis.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.83 Billion
Market Size 2030USD 2.40 Billion
CAGR 2025-20304.61%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

sJIA is a complex autoimmune condition primarily affecting children and is marked by systemic inflammation, high fevers, skin rashes, and joint pain, with potential complications including organ damage. The market spans a broad spectrum of therapeutic solutions, including pharmaceuticals, biologics, medical devices, and supportive care strategies aimed at improving patient outcomes and quality of life.

Key Market Drivers

Advancements in Biologic Therapies

The increasing global burden of chronic autoimmune diseases is a key contributor to the growth of the sJIA market. Although systemic JIA is a rare pediatric autoimmune condition, it benefits from broader developments in autoimmune disease research and treatment.

According to a study published in Frontiers in Immunology (PMC9918670), the incidence of autoimmune diseases has increased by 19.1%, with a 12.5% rise in prevalence annually. This trend has intensified global focus and investment in autoimmune research, accelerating the development of new treatment approaches for conditions such as sJIA.

Research into more common autoimmune disorders-such as lupus and rheumatoid arthritis-has uncovered shared immunological pathways that are informing the development of novel and repurposed therapies for sJIA. Healthcare systems are also shifting toward integrated, patient-centered chronic disease management models, prioritizing early diagnosis, personalized care plans, and coordinated treatment approaches.

In the United States, the CDC reports that approximately 220,000 children and adolescents live with arthritis-related conditions, including sJIA (MMWR Morb Mortal Wkly Rep 2023;72:793-798). This growing pediatric population is prompting improved screening and referral systems, which in turn are enhancing early detection and treatment outcomes.

Pharmaceutical companies are responding to this demand by investing heavily in biologics and other targeted therapies specifically designed for pediatric autoimmune conditions. These innovations are reshaping the treatment landscape, improving clinical outcomes, and enhancing quality of life for affected children.

Key Market Challenges

High Treatment Costs

One of the most significant barriers to effective care in the Global sJIA Market is the high cost associated with treatment. Managing sJIA typically involves a comprehensive, multidisciplinary approach, including medications to control systemic inflammation and prevent long-term complications.

A major cost driver is the use of biologic therapies, particularly IL-1 and IL-6 inhibitors, which have proven highly effective in treating sJIA. However, these advanced biologics are among the most expensive drugs on the market and often require long-term administration, leading to a substantial financial burden for patients and healthcare systems.

Beyond the cost of medications, managing sJIA often involves routine monitoring, imaging studies, physical therapy, and consultations with multiple specialists. These ancillary costs can further strain healthcare budgets and impose significant financial challenges on families.

Key Market Trends

Personalized Medicine

Personalized medicine is increasingly shaping the future of the sJIA market by offering more tailored and effective treatment approaches based on an individual's genetic, molecular, and clinical profile. This patient-specific strategy is helping optimize therapeutic outcomes while reducing risks associated with traditional trial-and-error treatment methods.

In sJIA care, the use of advanced molecular and genetic profiling tools enables clinicians to better understand disease mechanisms and identify actionable molecular targets. This facilitates the development of highly specialized treatment plans that address the unique disease pathways of each patient.

A key advantage of personalized medicine is its predictive capability-allowing healthcare providers to determine which patients are most likely to respond favorably to specific biologics or immunosuppressive therapies. This not only enhances treatment efficacy but also reduces exposure to ineffective medications and associated side effects.

Furthermore, personalized dosing strategies ensure that patients receive the most appropriate therapeutic regimen, enhancing treatment safety and improving overall patient outcomes. As this approach becomes more widely adopted, it is expected to significantly advance the management of sJIA and reinforce the market's growth trajectory.

Key Market Players

Report Scope:

In this report, the Global Systemic Juvenile Idiopathic Arthritis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Systemic Juvenile Idiopathic Arthritis Market, By Treatment Type:

Global Systemic Juvenile Idiopathic Arthritis Market, By Route of Administration:

Global Systemic Juvenile Idiopathic Arthritis Market, By Distribution Channel:

Global Systemic Juvenile Idiopathic Arthritis Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Systemic Juvenile Idiopathic Arthritis Market.

Available Customizations:

Global Systemic Juvenile Idiopathic Arthritis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Systemic Juvenile Idiopathic Arthritis Market Outlook

6. North America Systemic Juvenile Idiopathic Arthritis Market Outlook

7. Europe Systemic Juvenile Idiopathic Arthritis Market Outlook

8. Asia-Pacific Systemic Juvenile Idiopathic Arthritis Market Outlook

9. South America Systemic Juvenile Idiopathic Arthritis Market Outlook

10. Middle East and Africa Systemic Juvenile Idiopathic Arthritis Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. PESTLE Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

16. Strategic Recommendations

17. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â